Edgardo Castillo, MD
Internal Medicine · Lehigh Acres, FLNPI 1508039819
Payments from drug & device makers
Across 99 payments — averaging $2848.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$261K
- Regeneron$13K
- Eli Lilly$6K
- AstraZeneca$362
- AbbVie$308
- Gilead$223
- plus $1K from 24 others
Across 1 payment — averaging $8850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9K
What the payments were for
- Food & beverage$2,04099%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $260,878 |
| Regeneron | 4 | $12,706 |
| Eli Lilly | 3 | $6,374 |
| AstraZeneca | 13 | $362 |
| AbbVie | 9 | $308 |
| Gilead | 3 | $223 |
| Novo Nordisk | 10 | $203 |
| Lilly USA, LLC | 9 | $129 |
| Abbott | 5 | $97 |
| Scilex Pharmaceuticals Inc. | 4 | $64 |
| Dexcom, Inc. | 3 | $63 |
| Boehringer Ingelheim | 4 | $63 |
| Pfizer | 3 | $54 |
| Johnson & Johnson(2 entities) | 2 | $53 |
| Bayer | 2 | $39 |
| Corcept Therapeutics | 2 | $39 |
| Forte Bio-pharma LLC | 2 | $35 |
| Merck | 2 | $33 |
| Almatica Pharma LLC | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
| Amgen | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Exact Sciences | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$281,980 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $95,076 |
| JanuviaSitagliptin Phosphate | 59 | $86,319 |
| TrulicityDulaglutide | 25 | $50,047 |
| FarxigaDapagliflozin Propanediol | 34 | $44,950 |
| OzempicSemaglutide | 33 | $42,557 |
| Dexlansoprazole DrDexlansoprazole | 88 | $37,229 |
| EliquisApixaban | 26 | $34,429 |
| TradjentaLinagliptin | 30 | $32,066 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $22,051 |
| EntrestoSacubitril/Valsartan | 13 | $18,013 |
| LinzessLinaclotide | 25 | $15,372 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $10,885 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 40 | $8,416 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,717 |
| VascepaIcosapent Ethyl | 16 | $6,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $63 | $127,14292 claims |
| MerckJanuvia, Janumet | $33 | $108,37074 claims |
| Lilly USA, LLCTrulicity | $129 | $50,04725 claims |
| AstraZenecaFarxiga, Symbicort | $362 | $48,15448 claims |
| Novo NordiskOzempic | $203 | $42,55733 claims |
| PfizerEliquis | $54 | $34,42926 claims |
| NovartisEntresto | $260,878 | $18,01313 claims |
| AbbVieLinzess | $308 | $15,37225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lehigh Acres
- Pedro YlisastiguiLehigh Acres$7.3M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.